Centric Wealth Management Takes Position in MAIA Biotechnology, Inc. $MAIA

Key Points

• Centric Wealth Management purchased 796,723 shares of MAIA Biotechnology in the second quarter, worth approximately $1.11 million and representing a 1.31% stake.
• Other institutional investors also added or initiated positions, bringing total institutional ownership to 5.65%. CEO Vlad Vitoc and Director Stan Smith separately bought shares, contributing to $204,233 in insider purchases over the past three months.
• MAIA shares opened at $1.40, with a market capitalization of about $85.2 million; the clinical-stage biotechnology company is developing antibody-based diagnostic and targeted radiotherapeutic treatments for cancer.

Centric Wealth Management purchased a new position in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 796,723 shares of the company's stock, valued at approximately $1,107,000. Centric Wealth Management owned 1.31% of MAIA Biotechnology as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of MAIA. PVG Asset Management Corp acquired a new stake in MAIA Biotechnology in the first quarter valued at $46,000. Corsair Capital Management L.P. bought a new stake in shares of MAIA Biotechnology in the 1st quarter valued at about $140,000. Jane Street Group LLC bought a new stake in shares of MAIA Biotechnology in the 4th quarter valued at about $120,000. Geode Capital Management LLC increased its stake in shares of MAIA Biotechnology by 9.5% in the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company's stock valued at $454,000 after buying an additional 25,684 shares during the period. Finally, Ritholtz Wealth Management bought a new position in shares of MAIA Biotechnology during the fourth quarter worth about $35,000. Institutional investors own 5.65% of the company's stock.

MAIA Biotechnology Price Performance

MAIA Biotechnology stock opened at $1.40 on Friday. The stock's 50 day moving average is $1.36 and its 200 day moving average is $1.51. The firm has a market cap of $85.16 million, a P/E ratio of -2.26 and a beta of 0.24. MAIA Biotechnology, Inc. has a one year low of $0.87 and a one year high of $3.19.

Insider Buying and Selling

In other news, CEO Vlad Vitoc purchased 72,700 shares of the stock in a transaction on Monday, June 1st. The stock was purchased at an average price of $1.39 per share, for a total transaction of $101,053.00. Following the acquisition, the chief executive officer owned 976,121 shares in the company, valued at $1,356,808.19. This trade represents a 8.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stan Smith purchased 75,000 shares of the stock in a transaction on Monday, June 1st. The shares were purchased at an average price of $1.34 per share, with a total value of $100,500.00. Following the acquisition, the director owned 1,519,178 shares in the company, valued at approximately $2,035,698.52. The trade was a 5.19% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 149,700 shares of company stock valued at $204,233 in the last three months. Insiders own 19.81% of the company's stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.

Want to see what other hedge funds are holding MAIA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source